EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design of Anti-Tumor RNA Nanoparticles and Their Inhibitory Effect on Hep3B Liver Cancer

Shuyi Sun, Ling Yan, Zhekai Liu iD, Weibo Jin iD

Biomolecules · 2025

DOI: 10.3390/biom16010045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Shuyi Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Plant Secondary Metabolism and Regulation of Zhejiang Province, College of Life Sciences and Medicine, Zhejiang Sci-Tech University…. Hauptthemen laut MEDLINE: Nanoparticles, Liver Neoplasms, RNA, Small Interfering, Carcinoma, Hepatocellular. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Sciences Foundation of China, National Natural Sciences Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA interference (RNAi) holds promise as a gene-silencing therapy for liver cancer but faces challenges related to siRNA instability, short half-life, and inefficient cellular uptake. In this study, we designed a self-assembling RNA nanoparticle targeting three oncogenes—hTERT, BIRC5, and FGFR1—key drivers of cancer progression. These RNA nanoparticles demonstrated enhanced stability and specificity, eliminating the need for conventional toxic delivery carriers. Functional assays revealed that the nanoparticles effectively suppressed the proliferation, migration, tumor growth and apoptosis of a Hepatocellular carcinoma cell line, Hep3B. The nanoparticles exhibited excellent safety and efficacy in xenograft model mice, without off-target toxicity. This work introduces a scalable, biocompatible RNA nanoparticle platform with multi-targeting capability, paving the way for improved RNAi-based therapeutics. Our findings offer a promising strategy for advancing personalized cancer therapies and underscore the broader potential of RNA nanotechnology in addressing complex malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLiver NeoplasmsRNA, Small InterferingCarcinoma, HepatocellularAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorSurvivinRNA InterferenceApoptosisCell ProliferationReceptor, Fibroblast Growth Factor, Type 1Xenograft Model Antitumor AssaysTelomerase

Stichwörter der Autor:innen

BIRC5FGFR1RNA nanoparticlesRNAi therapyhTERTliver cancer

Substanzen

SurvivinRNA, Small InterferingBIRC5 protein, humanReceptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanTelomeraseAntineoplastic Agents

Autor:innen und Institutionen

  • Key Laboratory of Plant Secondary Metabolism and Regulation of Zhejiang Province, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
  • Zhejiang Sci-Tech University Shaoxing Academy of Biomedicine, Shaoxing 312366, China.

ORCID-Profile: Zhekai Liu, Weibo Jin

Förderung

  • the Natural Sciences Foundation of China
  • National Natural Sciences Foundation of China

Zitieren

APA

Sun, S., Yan, L., Liu, Z., & Jin, W. (2025). Design of Anti-Tumor RNA Nanoparticles and Their Inhibitory Effect on Hep3B Liver Cancer. Biomolecules. https://doi.org/10.3390/biom16010045

Vancouver

Sun S, Yan L, Liu Z, Jin W. Design of Anti-Tumor RNA Nanoparticles and Their Inhibitory Effect on Hep3B Liver Cancer. Biomolecules. 2025. doi:10.3390/biom16010045

BibTeX
@article{Sun2025,
  author = {Sun, Shuyi and Yan, Ling and Liu, Zhekai and Jin, Weibo},
  title = {Design of Anti-Tumor RNA Nanoparticles and Their Inhibitory Effect on Hep3B Liver Cancer},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom16010045}
}
Kostenlos starten →